$4.75M Ferring, Aventis Antitrust Settlement Earns Approval

Law360, New York (December 19, 2013, 3:52 PM EST) -- A $4.75 million settlement that Ferring BV and Aventis Pharmaceuticals Inc. struck with indirect purchasers of an antidiuretic won approval from a New York federal judge Wednesday, ending a class action accusing the drugmakers of suppressing the drug's generic competition by illegitimately obtaining a patent.

U.S. District Judge Cathy Seibel signed off on the deal, which also called for the class attorneys to receive $1.5 million in fees and nearly $104,000 in expenses from the settlement fund, despite objections from a group of insurance companies, including...
To view the full article, register now.